A Mab A Case Study In Bioprocess Development -

* INTRODUCTION. The Quality by Design (QbD) principle is a risk‐based approach to pharmaceutical development and manufacturing [1] National Institutes of Health (.gov)

During scale-up, an increase in acidic charge variants was observed in the 2,000 L bioreactor. Trace element analysis revealed that higher copper concentrations in the large-scale media accelerated basic variant conversion. Adjusting the copper supplementation down by 15% successfully realigned the charge variant profile with the clinical reference standard. 5. Conclusion and Key Takeaways

High-throughput automated single-cell deposition was used to ensure clonality, fulfilling strict regulatory requirements. Media and Feed Optimization

Defines the multidimensional interaction of process variables that ensure product quality, allowing for more flexible regulatory filings and operational robustness. Control Strategy: A Mab A Case Study In Bioprocess Development

The success of "A Mab" was not in any single step, but in the systematic, risk-based integration of upstream and downstream unit operations — a blueprint for modern bioprocess development.

The bioprocessing field is in a period of rapid evolution, moving from traditional batch processes toward more efficient, flexible, and cost-effective models.

Out of 500 clones screened, Clone 17B shows the highest specific productivity (qP = 25 pg/cell/day). However, early batch cultures reveal a problematic metabolite profile: high lactate accumulation (4 g/L) and ammonia (2 mM). High lactate inhibits cell growth and reduces final titers. * INTRODUCTION

Modern approaches rely on . The spokesperson from Boehringer Ingelheim notes that the best approach to ensuring scalability is to use a standardized platform rather than developing a unique process for every molecule. Established platform processes, such as those using single-use bioreactors from Thermo Fisher, are engineered to maintain comparable performance across a wide volume range, which helps to manage risk and speed up development timelines significantly.

Using a 0.2 cm bed height of multimodal resin (Capto Adhere) at pH 5.5.

The first critical step is cell line development. For A-mAb, a Chinese Hamster Ovary (CHO) cell line is engineered to express the antibody. However, not all cell clones are equal; they vary significantly in their growth characteristics, productivity, and the quality of the antibody they produce. To find the "super-producer," scientists use high-throughput screening systems like the . This allows them to run hundreds of parallel cultures to identify clones with the highest titer and the most favorable quality attributes. Using Design of Experiments (DoE)

Centrifugation (depth filtration as backup) → 0.2 µm filtration.

One critical insight: Routine HCP ELISA does not detect a specific CHO protein (Cathepsin D) that co-elutes with Mab-X during AEX. The team adds a secondary orthogonal method (LC-MS/MS) to verify HCP clearance.

For bioprocess engineers and scientists, every new Mab is a new case study. And every case study, like Mab-X, is a step toward safer, more affordable biologics for patients worldwide.

The development team shifts from a traditional batch process to a fed-batch process with a chemically defined, animal-component-free medium. Using Design of Experiments (DoE), they optimize the feed strategy:

A humanized IgG1 monoclonal antibody (mAb) targeting the immune checkpoint protein PD-L1, indicated for solid tumors. Challenge: The original lead candidate, produced in murine ascites, had low productivity (0.2 g/L) and high immunogenicity risk. The goal: develop a scalable, GMP-compliant process for Phase I clinical trials with a target titer >3 g/L and ≥95% purity.